Get started
Author

Carolin Svensson

Observed name: Caroline Svensson
Institution: BioInvent (Sweden)
ORCID: 0009-0000-8434-8503
Observed ORCID: 0009-0000-8434-8503
OpenAlex ID: A5062770901
Deep Mining of Complex Antibody Phage Pools Generated by Cell Panning Enables Discovery of Rare Antibodies Binding New Targets and Epitopes
2019 · Anne Ljungars, Carolin Svensson, et al. · Frontiers in Pharmacology · 37
PDF
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
2022 · Monika Semmrich, Jean-Baptiste Marchand, et al. · Journal for ImmunoTherapy of Cancer · 36
PDF
Human MHC Class II and Invariant Chain Knock‐in Mice Mimic Rheumatoid Arthritis with Allele Restriction in Immune Response and Arthritis Association
2024 · Laura Romero‐Castillo, Taotao Li, et al. · Advanced Science · 15
PDF
Abstract 936: Targeting TNFR2 for cancer immunotherapy: Ligand blocking depletors versus receptor agonists
2020 · Linda Mårtensson, Kirstie Cleary, et al. · Cancer Research · 10
725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy
2020 · Linda Mårtensson, Mathilda Kovacek, et al. · Journal for ImmunoTherapy of Cancer · 9
Tolerogenic antigen-specific vaccine induces VISTA-enriched regulatory T cells and protects against arthritis in DRB1∗04:01 mice
2025 · Laura Romero-Castillo, Rajan Kumar Pandey, et al. · Molecular Therapy · 6
Anti-Tumoral Treatment with Thioredoxin Reductase 1 Inhibitor Auranofin Fosters Regulatory T Cell and B16F10 Expansion in Mice
2025 · Michael Y. Bonner, Tamas Vancsik, et al. · Antioxidants · 4
Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al. · Cancer Research · 3
1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy
2023 · Linda Martensson, Petra Holmkvist, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Sequence enrichment profiles enable target-agnostic antibody generation for a broad range of antigens
2023 · Jenny Mattsson, Anne Ljungars, et al. · Cell Reports Methods · 3
Abstract 4156: BI-1808 - a first in class ligand-blocking αTNFR2 antibody for cancer immunotherapy
2022 · Linda Mårtensson, Kirsty Cleary, et al. · Cancer Research · 3
Abstract 3567: Comprehensive preclinical studies of BT-001: An oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
2022 · Jean-Baptiste Marchand, Monika Semmrich, et al. · Cancer Research · 1
746 Vectorized Treg-depleting anti-CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
2021 · Monika Semmrich, Jean-Baptiste Marchand, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Supplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Table 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Data from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 10 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors
2026 · Ingrid Teige, Kristoffer S. Rohrberg, et al. · Clinical Cancer Research
Supplementary Fig 9 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 7 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 2 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Works count: 29
Citation count: 131
H-index: 6
I10-index: 4
Year
Topic
Type